Evidence map›Paper›PMID 23995098›Full record

ArticleBone marrow transplantation2014

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.

G Kunter, J B Perkins, J Pidala, T Nishihori, M A Kharfan-Dabaja, T Field, H Fernandez, L Perez, F Locke, E Ayala and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?Current hematologic malignancy reports · 2017
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

G Kunter1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
J B Perkins1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
J Pidala1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
T Nishihori1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
M A Kharfan-Dabaja1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
T Field1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
H Fernandez1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
L Perez1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
F Locke1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
E Ayala1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
M Tomblyn1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
J L Ochoa-Bayona1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
B Betts1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
M Nieder1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
C Anasetti1] Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [2] Oncologic Sciences, University of South Florida, Tampa, FL, USA.
Moffitt Cancer Center · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation offers improved survival in patients with ALL, but with regimens containing TBI, the nonrelapse mortality is 20-40%. Efforts to lessen transplant toxicities by reducing conditioning regimen intensity have led to increased relapse risk. Therefore, there is a need for less toxic regimens that maintain an anti-leukemia effect. We report here a retrospective review of 65 patients with ALL in first remission receiving grafts from allogeneic donors after fludarabine 40 mg/m(2)/day for 4 days and i.v. BU targeted to a median daily area under the concentration-time curve below 6000 μmoles min/L. At 2 years after transplantation, OS was 65% (95% confidence interval (CI): 52-77%), relapse-free survival was 61% (95% CI: 48-73%), cumulative incidence of relapse was 26% (95% CI: 17-39%) and cumulative incidence of nonrelapse mortality was 14% (95% CI: 8-26%). Age over 35 years, Ph chromosome positivity and minimal residual disease at transplant did not adversely affect outcomes. Pharmacokinetically targeted BU and fludarabine can provide intensive pre-transplant conditioning for adults with ALL in first remission, with promising relapse-free and OS rates.

Indexed as

AdultAgedBusulfanDisease-Free SurvivalDose-Response Relationship, DrugFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsMaleMiddle AgedNeutrophilsPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRecurrenceBusulfanfludarabineImmunosuppressive AgentsVidarabine

Identifiers

PMID23995098
OpenAlexW2090022119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.